An observational study in Myopia, sponsored by Santen SAS. Completed at 10 sites in 7 countries. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Observational
This study aims to assess the impact of myopia in childhood and its long-term complications in adulthood on health-related Quality of Life (HRQoL), providing valuable data for cost-effectiveness models. It will gather country-specific information on healthcare resource utilization, including treatment costs, access to care, and reimbursement policies. In addition, the study will examine how myopia and its treatments affect daily activities and evaluate treatment satisfaction. No data on the efficacy of myopia treatments is collected in this study, and neither is the occurrence of adverse events.
1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.
This study's enrollment of 344 is above the median of 150 across 204 observational studies indexed under Myopia.
Browse Myopia studies →Santen SAS is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
First submitted after Santen Inc. became part of Santen Pharmaceutical Co., Ltd..
Counted across the registry records on this site, refreshed daily.
Children or adolescents aged 5 years or older suffering from myopia (low, moderate, or high myopia) and adults suffering from myopia and its complications such as: cataract, macular degeneration, open-angle glaucoma, retinal detachment, and legal blindness/severe visual impairment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Parents (or other proxy) of children or adolescents aged 5 years or older suffering from myopia (low, moderate, or high myopia) defined by their refractive error;
Other: Non-Intervention
Adults suffering from myopia and its complications such as: cataract, macular degeneration, open-angle glaucoma, retinal detachment, and legal blindness/severe visual impairment.
Other: Non-Intervention
Non-Intervention study
Group 1 respondents' assessment of EQ-5D-Y-3L (proxy)
Group 1 respondents are parents (or other proxy) of children and adolescents suffering from myopia. The EQ-5D-Y-3L (European Quality of Life 5 Dimensions 3 Level) proxy version is an instrument used to assess health-related quality of life (HRQoL) of children and adolescents from the perspective of a parent, caregiver or another proxy. It uses a three-level scale (no problems, some problems or a lot of problems) along with a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health). The EQ-5D-Y-3L value sets will be used to calculate utility values.
Time frame: Through study completion, an average of 6 months
Group 1 respondents' assessment of Bolt-on vision
Group 1 respondents are parents (or other proxy) of children and adolescents suffering from myopia. The vision bolt-on assessment is an extension to the EQ-5D tool to specifically address the impact of vision impairment on a person's quality of life and consists of a single question in the same format.
Time frame: Through study completion, an average of 6 months
Group 1 respondents' assessment of PedEyeQ (Pediatric Eye Questionnaire)
Group 1 respondents are parents (or other proxy) of children and adolescents suffering from myopia. The PedEyeQ (Pediatric Eye Questionnaire) proxy version is a HRQoL (Health Related Quality of Life) assessment tool specifically designed to measure the impact of pediatric eye conditions on children. The tool consists of age-appropriate questionnaires (5-11 years old and 12-17 years old) that assess how vision problems affect daily activities, social interactions, school performance, and overall well-being of the child.
Time frame: Through study completion, an average of 6 months
Group 2 respondents' assessment of EQ-5D-5L
Group 2 respondents are adult patients suffering from myopia and a long-term complication of myopia. The EQ-5D-5L (European Quality of Life 5 Dimensions 3 Level) includes five questions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. This questionnaire will be administered to adults suffering from myopia plus a complication. Each domain is rated from 1 (best quality) to 5 (worst quality), along with a VAS from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Through study completion, an average of 6 months
Group 2 respondents' assessment of Bolt-on vision
Group 2 respondents are adult patients suffering from myopia and a long-term complication of myopia. The vision bolt-on is an extension to the EQ-5D tool to specifically address the impact of vision impairment on a person's quality of life. The EQ-5D-5L value sets will be used to calculate utility values for adults with myopia and its complications.
Time frame: Through study completion, an average of 6 months
Group 2 respondents' assessment of NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25)
Group 2 respondents are adult patients suffering from myopia and a long-term complication of myopia. The NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25) is a tool used to assess VRQoL (Vision Related Quality of Life) in individuals aged 18 and older. It consists of 25 items that measure the impact of vision impairment on daily activities and well-being across 12 domains, including visual function, mental health, social functioning, and role limitations. The NEI-VFQ-25 helps evaluate how visual problems affect a person's ability to perform tasks like reading, driving, and interacting socially.
Time frame: Through study completion, an average of 6 months
Ran from Jul 2025 to primary completion in Apr 2026, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.